Specific KRAS-Mutant Cancers Are Sensitive to Inhibition of V-type ATPases

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ras mutations are common drivers in various cancers.
• V-adenosine triphosphatase (V-ATPase) is crucial for cellular processes, including cancer cell survival and proliferation.
• Targeting V-ATPase presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To identify and characterize novel agents selectively targeting Ras-mutant cancer cells.
• To investigate the mechanism of action of the identified agent, 249C.
• To evaluate the efficacy of 249C as a V-ATPase inhibitor in Ras-mutant contexts.

Main Methods:

• High-throughput screening to identify cytotoxic agents against Ras-mutant cancer cells.
• Biochemical assays to determine the binding affinity and inhibitory activity of 249C against V-ATPase.
• Cell-based assays to assess the cytotoxic effects of 249C on various cancer cell lines with and without Ras mutations.

Main Results:

• 249C was identified as a potent and selective cytotoxic agent against Ras-mutant cancer cells.
• 249C demonstrated direct binding to and inhibition of V-ATPase.
• Selective inhibition of V-ATPase by 249C led to significant cancer cell death in Ras-mutant models.

Conclusions:

• 249C represents a promising novel therapeutic agent for cancers harboring Ras mutations.
• The mechanism of action involves the selective inhibition of V-ATPase.
• Further investigation of 249C is warranted for its clinical development in oncology.